CONMED Non-GAAP EPS of $1.04 beats by $0.04, revenue of $335.6M misses by $0.65M (CNMD:NYSE)
CONMED reported Q3 Non-GAAP EPS of $1.04, beating estimates by $0.04, but revenue of $335.6M missed expectations by $0.65M. The company updated its full-year 2026 financial guidance based on Q3 performance and outlook.
How this was made
The 30-second read
Why it matters
The earnings release is the primary source of new information, making it highly relevant for short‑term traders.
Market read
First‑report earnings data for a U.S.-listed healthcare company; actionable for traders evaluating post‑earnings moves.
What to watch
Management's updated full‑year guidance may contain upside potential not reflected in the brief excerpt.
Background
CONMED released its Q3 2026 earnings, providing the first public disclosure of the quarter's results and an update to full‑year guidance.
Ticker impact
Q3 non‑GAAP EPS of $1.04 beat expectations by $0.04, while revenue of $335.6M missed by $0.65M and guidance was updated.
modest downside pressure as the revenue miss offsets the EPS beat
Investors often prioritize revenue trends; a miss, even small, can trigger sell pressure despite a modest EPS beat.
Market effects
Medical device sector may see slight scrutiny on revenue growth trends.
U.S. small‑cap healthcare stocks could experience modest volatility.
Limited to investors tracking U.S. healthcare equities.
Counterpoint
The EPS beat could signal underlying profitability strength, suggesting a buying opportunity despite the revenue miss.
Key entities
- CompanyCONMED Corporation
Medical device manufacturer reporting Q3 results.
